These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 26704388)

  • 1. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
    Ruvolo PP; Ruvolo VR; Benton CB; AlRawi A; Burks JK; Schober W; Rolke J; Tidmarsh G; Hail N; Davis RE; Andreeff M
    Biochim Biophys Acta; 2016 Apr; 1863(4):562-71. PubMed ID: 26704388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
    Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
    Tsao T; Shi Y; Kornblau S; Lu H; Konoplev S; Antony A; Ruvolo V; Qiu YH; Zhang N; Coombes KR; Andreeff M; Kojima K; Konopleva M
    Ann Hematol; 2012 Dec; 91(12):1861-70. PubMed ID: 22893484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L; Dittmann J; Vogler M; Fulda S
    Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
    Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
    Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.
    Bieghs L; Lub S; Fostier K; Maes K; Van Valckenborgh E; Menu E; Johnsen HE; Overgaard MT; Larsson O; Axelson M; Nyegaard M; Schots R; Jernberg-Wiklund H; Vanderkerken K; De Bruyne E
    Oncotarget; 2014 Nov; 5(22):11193-208. PubMed ID: 25008202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
    Wang Q; Wan J; Zhang W; Hao S
    Leuk Lymphoma; 2019 Sep; 60(9):2170-2180. PubMed ID: 30626241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
    Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
    Jin L; Tabe Y; Kojima K; Shikami M; Benito J; Ruvolo V; Wang RY; McQueen T; Ciurea SO; Miida T; Andreeff M; Konopleva M
    J Mol Med (Berl); 2013 Dec; 91(12):1383-97. PubMed ID: 23955073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LGALS1 acts as a pro-survival molecule in AML.
    Ruvolo PP; Ma H; Ruvolo VR; Zhang X; Post SM; Andreeff M
    Biochim Biophys Acta Mol Cell Res; 2020 Oct; 1867(10):118785. PubMed ID: 32590026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
    Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
    Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
    Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
    Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
    Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.